Bristol-Myers Squibb (NYSE:BMY) is joining forces with Illumina (NSDQ:ILMN) to develop and commercialize diagnostic tests to support Bristol’s portfolio of cancer drugs.
The companies announced last week that they plan to develop an assay to measure predictive genomic biomarkers, like tumor mutation burden, that could help doctors identify patients that will benefit from Bristol’s immunotherapies.
Get the full story at our sister site, Drug Delivery Business News.
The post Bristol-Myers Squibb, Illumina to develop companion diagnostics for immunotherapies appeared first on MassDevice.
from MassDevice https://ift.tt/2vexGmm
Cap comentari:
Publica un comentari a l'entrada